PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Provided By GlobeNewswire
Last update: Mar 13, 2025
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute
Second Versamune® platform candidate targets MUC1-positive solid tumors
Read more at globenewswire.com
